Arid
DOI10.1093/rheumatology/kem031
Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom
Botteman, M. F.; Hay, J. W.; Luo, M. P.; Curry, A. S.; Wong, R. L.; van Hout, B. A.
通讯作者Botteman, M. F.
来源期刊RHEUMATOLOGY
ISSN1462-0324
出版年2007
卷号46期号:8页码:1320-1328
英文摘要

Objectives. This study evaluated the cost effectiveness of adalimumab vs conventional therapy in patients with active ankylosing spondylitis (AS).


Methods. The analysis was based on pooled data from two Phase III studies of adalimumab in active AS. Patients with an inadequate response to >= 1 NSAID received adalimumab 40 mg every other week (n=246) or placebo (n=151) for 24 weeks. A microsimulation model was developed with patients being treated with adalimumab according to the International ASAS Consensus Statement and BSR guidelines. The pooled adalimumab data, as well as data from the Outcome Assessment in AS International Study (OASIS) database and the literature, were used to model patients’ BASDAI and BASFI scores and costs and health-related quality of life associated with various degrees of disease activity. Costs (in 2004 British) of AS, drug, administration, monitoring, hospitalization and AEs were calculated from the perspective of the UK NHS. Discounting was applied at 3.5% per year for costs and benefits as per the NICE reference case for economic evaluations. Uncertainty was addressed via sensitivity analyses.


Results. The incremental cost-effectiveness ratio (ICER) of adalimumab vs conventional therapy was estimated to improve with longer time horizons (48 weeks to 5 and 30 yrs). The central estimate was that, over 30 yrs, adalimumab therapy yielded 1.03 more quality-adjusted lifeyears (QALYs) per patient initiating therapy. Some AS treatment-related costs were estimated to be offset by adalimumab (at 10750 pound/ patient), leaving a total incremental cost (adalimumab vs conventional therapy) at 23857 pound per patient. The 30-yr ICER of adalimumab Vs conventional therapy was estimated at 23097 pound/QALY. Sensitivity analyses demonstrated robustness of results. When indirect costs were also included (analysis from societal perspective), ICER improved to 5093 pound/QALY.


Conclusions. This analysis indicates that adalimumab, when used according to UK treatment guidelines, is cost-effective vs conventional therapy for treating AS patients.


英文关键词ankylosing spondylitis adalimumab tumour necrosis factor antagonists cost effectiveness quality-adjusted life-years incremental cost-effectiveness ratio pharmacoeconomics United Kingdom treatment guidelines randomized controlled trials therapeutic biologics
类型Article
语种英语
国家USA ; Netherlands
收录类别SCI-E
WOS记录号WOS:000248686800021
WOS关键词PLACEBO-CONTROLLED TRIAL ; INFLIXIMAB ; ETANERCEPT ; EFFICACY ; DISABILITY ; SAFETY
WOS类目Rheumatology
WOS研究方向Rheumatology
资源类型期刊论文
条目标识符http://119.78.100.177/qdio/handle/2XILL650/155914
作者单位(1)Pharmerit N Amer LLC, Bethesda, MD USA;(2)Univ So Calif, Los Angeles, CA USA;(3)Abbott Labs, Abbott Pk, IL 60064 USA;(4)Abbott Labs, Parsippany, NJ USA;(5)Univ Utrecht, Med Ctr, Utrecht, Netherlands
推荐引用方式
GB/T 7714
Botteman, M. F.,Hay, J. W.,Luo, M. P.,et al. Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom[J],2007,46(8):1320-1328.
APA Botteman, M. F.,Hay, J. W.,Luo, M. P.,Curry, A. S.,Wong, R. L.,&van Hout, B. A..(2007).Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom.RHEUMATOLOGY,46(8),1320-1328.
MLA Botteman, M. F.,et al."Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom".RHEUMATOLOGY 46.8(2007):1320-1328.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Botteman, M. F.]的文章
[Hay, J. W.]的文章
[Luo, M. P.]的文章
百度学术
百度学术中相似的文章
[Botteman, M. F.]的文章
[Hay, J. W.]的文章
[Luo, M. P.]的文章
必应学术
必应学术中相似的文章
[Botteman, M. F.]的文章
[Hay, J. W.]的文章
[Luo, M. P.]的文章
相关权益政策
暂无数据
收藏/分享

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。